Key result
DOACs linked to lower dementia risk vs. warfarin in AF patients.
Why the study?
Although DOACs have been associated with a decreased risk of dementia compared to warfarin, it is unknown whether differences in dementia risk exist among individual DOACs in patients with AF.
Does the choice of individual DOAC (apixaban, edoxaban, or rivaroxaban) affect the incidence of dementia in patients with nonvalvular atrial fibrillation?
Does the choice of individual DOAC (apixaban, edoxaban, or rivaroxaban) affect the incidence of dementia in patients with nonvalvular atrial fibrillation?
Compares dementia risk among atrial fibrillation patients using different direct oral anticoagulants, suggesting important implications for treatment choices.
In patients with atrial fibrillation (AF), oral anticoagulation is essential for stroke prevention and may also prevent dementia. Although the class of direct oral anticoagulants (DOACs) have been associated with a decreased risk of dementia compared to warfarin, it is unknown if differences exist among the individual DOACs. Our primary objective was to compare the dementia risk among AF patients initiating different DOACs, with head-to-head comparisons between apixaban, edoxaban, and rivaroxaban.
No takes yet. Share an insight, caveat, or question.
Van et al. (2026) studied this question. Direct oral anticoagulants are associated with a decreased risk of dementia compared to warfarin in patients with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: